[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600883":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":30,"collaborators":25,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":25,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":25,"enrollmentInfo":42,"targetDuration":25,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":25},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference Drug(AD-1161), Period 2 : Test Drug(AD-116)",[13,14],"Drug: AD-116","Drug: AD-1161",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Period 1 : Test Drug(AD-116), Period 2 : Reference Drug(AD-1161)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-116","AD-116 Oral Tablet",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-1161","AD-1161 Oral Capsule",[9,16],{"type":31,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100600883","phase-1-a-clinical-trial-to-evaluate-the-safety-and-the-pharmacokinetics-of-ad-116-compared-to-ad-1161-in-healthy-adult-male-volunteers-100600883",false,"NCT07103278","A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"MALE","19 Years",{"count":43,"type":44},44,"ESTIMATED","INTERVENTIONAL",[47],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers",[50],"Benign Prostatic Hyperplasia","NOT_YET_RECRUITING","2025-09-30",{"date":54,"type":55},"2025-10-03","ACTUAL",{"date":57,"type":44},"2025-12",{"date":59,"type":44},"2026-01",{"name":5,"class":6}]